| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
PLD[1]
VU0364739 selectively targets the phospholipase D2 (PLD2) isoform. It is a potent inhibitor, with a cellular IC50 of 20-22 nM, exhibiting over 75-fold selectivity over the PLD1 isoform. PLD2 is involved in a wide array of cellular functions including signal transduction, membrane trafficking, and cytoskeletal reorganization. By selectively inhibiting PLD2, this compound helps researchers dissect its unique biological roles separate from PLD1. |
|---|---|
| ln Vitro |
In vitro, VU0364739 is a potent, selective, and allosteric inhibitor of phospholipase D2 (PLD2). It exhibits a cellular IC50 of 20-22 nM, with over 75-fold selectivity over PLD1. This high level of isoform selectivity makes it an ideal chemical probe. Furthermore, its activity has been shown to reduce the growth and proliferation of cancer/tumor cells, highlighting its potential in cancer research and as a tool to study the role of PLD2 in cell proliferation.
|
| ln Vivo |
In vivo activity data for VU0364739 is not detailed in the provided sources. As a potent and selective PLD2 inhibitor, it has the potential to reduce tumor growth in xenograft mouse models of cancer. Researchers would typically administer it via intraperitoneal or oral routes to animal models to study its impact on cancer progression, as well as its effects on neurological and immune functions where PLD2 is implicated.
|
| Enzyme Assay |
The inhibitory activity of VU0364739 against PLD2 can be confirmed using an in vitro PLD activity assay. Membranes from cells overexpressing human PLD2 are incubated with varying concentrations of VU0364739 (e.g., 0.1-1000 nM) in a reaction buffer containing phosphatidylcholine substrate and a detergent like Triton X-100. The reaction is allowed to proceed, and the production of phosphatidic acid (PA) is measured using a fluorescent or radiolabeled detection method. The cellular IC50 is 20-22 nM.
|
| Cell Assay |
For cell-based assays, cancer cells such as breast, lung, or ovarian cancer lines are seeded in 96-well plates. They are treated with VU0364739 at concentrations around its IC50 (e.g., 0.01-10 uM) for 48-72 hours. Cell proliferation and viability are then measured using a standard MTT or CellTiter-Glo luminescent assay. A reduction in cell viability would confirm the compound's effect on cancer cell growth. Researchers can also measure PA levels in the cell lysates using mass spectrometry as a direct pharmacodynamic readout.
|
| Animal Protocol |
In vivo efficacy studies for VU0364739 would typically be performed using a xenograft mouse model of human cancer. Mice are subcutaneously implanted with human cancer cells (e.g., lung or ovarian). When tumors reach a predetermined volume, mice are randomized and treated with VU0364739 or a vehicle control. The compound would be formulated in a suitable vehicle (e.g., 10% DMSO, 40% PEG300, 5% Tween-80, 45% saline) and administered via intraperitoneal injection at doses of 5-50 mg/kg once daily. Tumor volume is measured with calipers twice weekly to assess anti-tumor efficacy.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for VU0364739 is not publicly available. The compound has a molecular weight of 446.52 g/mol. It is soluble in DMSO (200 mg/mL). For in vivo studies, a formulation using DMSO and co-solvents will be necessary. Researchers should conduct pilot PK studies to determine key parameters such as half-life, Cmax, and oral bioavailability in their specific animal model.
|
| Toxicity/Toxicokinetics |
Published toxicology data for VU0364739 is limited. In cell-based assays, it reduces cancer cell growth, which is the intended effect. The high selectivity for PLD2 over PLD1 is expected to minimize off-target toxicity, as PLD1 is thought to mediate many of the redundant or housekeeping functions of the PLD family. Standard safety precautions for handling research chemicals should be followed.
|
| References | |
| Additional Infomation |
VU0364739 is a research-grade compound and is not approved for clinical use. It is a best-in-class chemical probe for studying the specific biological functions of the PLD2 isoform in a wide range of fields, including cancer biology, immunology, and neurobiology. The compound should be stored as a powder at -20degC, protected from light and moisture. For research use only.
|
| Molecular Formula |
C26H27FN4O2
|
|---|---|
| Molecular Weight |
446.52
|
| Exact Mass |
446.212
|
| CAS # |
1244639-78-8
|
| Related CAS # |
VU 0364739 hydrochloride;1244640-48-9
|
| PubChem CID |
46937439
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.859
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
710
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CN(CCC12C(=O)NCN2C3=CC(=CC=C3)F)CCNC(=O)C4=CC5=CC=CC=C5C=C4
|
| InChi Key |
MSTXJJGAXXJCBY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H27FN4O2/c27-22-6-3-7-23(17-22)31-18-29-25(33)26(31)10-13-30(14-11-26)15-12-28-24(32)21-9-8-19-4-1-2-5-20(19)16-21/h1-9,16-17H,10-15,18H2,(H,28,32)(H,29,33)
|
| Chemical Name |
N-[2-[1-(3-fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl]ethyl]naphthalene-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 200 mg/mL (447.91 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2395 mL | 11.1977 mL | 22.3954 mL | |
| 5 mM | 0.4479 mL | 2.2395 mL | 4.4791 mL | |
| 10 mM | 0.2240 mL | 1.1198 mL | 2.2395 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
